Brief: Belite Bio Completes Enrollment In Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant For Stargardt Disease
24/07/2023 11:09
July 24 (Reuters) - Belite Bio Inc BLTE.O :
* BELITE BIO COMPLETES ENROLLMENT IN PIVOTAL GLOBAL PHASE 3
DRAGON
TRIAL EVALUATING ORAL TINLAREBANT FOR STARGARDT DISEASE
* BELITE BIO INC - INTERIM SAFETY AND EFFICACY DATA FROM
PHASE 3
"DRAGON" TRIAL FOR STGD1 IS EXPECTED IN MID-2024
* BELITE BIO INC - PLANS TO HAVE FIRST PATIENT ENROLLED IN
2-YEAR
PHASE 3 STUDY (PHOENIX) OF TINLAREBANT IN GEOGRAPHIC ATROPHY
(GA) IN Q3 OF 2023
* BELITE BIO INC - TOPLINE DATA FOR TINLAREBANT IN PHASE 2
STGD1
STUDY IS EXPECTED IN Q4 OF 2023
Source text for Eikon: ID:nGNXbHn7XC
Further company coverage: BLTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses